News
Press Releases
May 22, 2022
Fractyl Health Presents New Mechanistic Data on Revita® DMR in Type 2 Diabetes
...
Read MoreMay 17, 2022
Fractyl Health to Present New Data on Revita® DMR in Type 2 Diabetes at Digestive Disease Week 2022
Fractyl Health, an organ-editing metabolic therapeutics company focused on pioneering a new approach to the treatment of type 2 diabetes (T2D), will share new data in an oral presentation during the 2022 Digestive Diseas...
Read MoreFeb 8, 2022
Fractyl Health Receives Reimbursement Authorization in Germany for Revita DMR® System
...
Read MoreJan 18, 2022
Fractyl Health Provides Initial Clinical Update on Open-Label REVITA-T2Di
Fractyl Health, an organ-editing metabolic therapeutics company focused on pioneering a new approach to the treatment of type 2 diabetes (T2D), announced today initial interim feasibility data from human clinical experie...
Read MoreJan 12, 2022
Fractyl Health Appoints Kelly Barnes to the Company’s Board of Directors
Fractyl Health, an organ editing metabolic therapeutics company focused on pioneering a new approach to the treatment of type 2 diabetes (T2D), today announced the appointment of Kelly Barnes to the company’s board of ...
Read MoreNov 30, 2021
Fractyl Health Announces the FDA’s Authorization of Expanding the Revitalize-1 Study’s Sample Size
LEXINGTON, Mass., November 30, 2021 - Fractyl Health, an organ-editing metabolic therapeutics company focused on pioneering a new approach to the treatment of type 2 diabetes (T2D), announced today the United States Food...
Read MoreOct 27, 2021
Fractyl Health Announces Publication of Pioneering New Model of Intestine’s Role in Metabolism
LEXINGTON, Mass., October 27, 2021 – Fractyl Health, a life sciences company dedicated to developing novel therapeutic interventions aimed at reversing the metabolic disease epidemic, including type 2 diabetes (T2D), t...
Read More